On January 20-21, Washington, D.C. became the stage for the inaugural meeting of the U.S.-India Drug Policy Executive Working Group. This gathering, convened under the auspices of the Office of National Drug Control Policy (ONDCP), was launched by Director Sara Carter, who underscored the united front of President Trump and Prime Minister Modi against the dual threats of narco-terrorism and illicit drug trafficking. Ambassador Vinay Kwatra of India made it clear that combating narcotics trafficking and regulating precursor chemicals ranks high on India’s agenda, all while ensuring that legitimate trade is not unduly hampered. The Executive Working Group, co-led by ONDCP’s Acting Deputy Director Debbie Seguin and Deputy Director General Monika Ashish Batra from India’s Narcotics Control Bureau, set out to forge actionable strategies that would solidify the critical counter-narcotics partnership between the two nations.
Director Carter articulated a stark reality: “The drug crisis is now a core national security priority.” This Executive Working Group represents a strategic endeavor to leverage bilateral ties not only to protect families but also to bolster legitimate industries that can thrive even in the shadow of drug-related challenges.
Both nations have pledged to enhance their cooperation in dismantling the networks responsible for illegal drug production and trafficking, as well as the diversion of precursor chemicals that jeopardize public safety. Central to their strategy is a comprehensive, whole-of-government approach that ensures seamless collaboration across agencies and governments, while also safeguarding the pharmaceutical supply chain in accordance with national regulations. This meeting builds on the successes of recent joint operations aimed at undermining illicit drug trafficking networks, demonstrating a proactive stance rather than a reactive one.
This inaugural meeting serves as a testament to the unwavering commitment of both the United States and India to tackle the global drug crisis, forging a path toward a safer and healthier future for both nations. In an era where the stakes of drug policy are intertwined with national security, such collaborative initiatives are not just beneficial—they are essential.
